Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Huadong Medicine Enters $83 Million Deal for GLP-1r Diabetes Treatment

publication date: Dec 22, 2017

Huadong Medicine signed an $83 million agreement to acquire China/Western Asia rights for a diabetes 2 treatment developed by vTv Therapeutics of North Carolina. TTP273 is an oral GLP-1r agonist. Huadong will pay $8 million upfront and be responsible for an additional $75 million in milestones plus royalties. TTP273 has successfully completed a US Phase II trial, providing a statistically significant reduction in HbA1c in type 2 diabetics. More details....

Stock Symbols: (SZE: 000963) (NSDQ: VTVT)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.